A standardized kit for automated quantitative assessment of candidate protein biomarkers in human plasma

Bioanalysis

Volumn 7, Issue 23, 2015, Pages 2991-3004

  Percy, Andrew J ^a   Mohammed, Yassene ^a,b   Yang, Juncong ^a   Borchers, Christoph H ^a,c  

^a UNIVERSITY OF VICTORIA   (Canada)

^b LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^c UNIVERSITY OF VICTORIA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; PLASMA PROTEIN; PROTEIN;

ARTICLE; AUTOMATION; CONTROLLED STUDY; HUMAN; ISOTOPE LABELING; LIMIT OF QUANTITATION; LIQUID CHROMATOGRAPHY; MASS SPECTROMETRY; MULTIPLE REACTION MONITORING; PLASMA; QUANTITATIVE ANALYSIS; REPRODUCIBILITY; BLOOD; QUALITY CONTROL; STANDARD;

BIOMARKERS; BLOOD PROTEINS; HUMANS; QUALITY CONTROL; REFERENCE STANDARDS;

EID: 84949663216     PISSN: 17576180     EISSN: 17576199     Source Type: Journal    
DOI: 10.4155/bio.15.222     Document Type: Article

References (61)

1. Gillette MA, Carr SA. Quantitative analysis of peptides and proteins in biomedicine by targeted mass spectrometry. Nat. Meth. 10, 28-34 (2013).
2. Picotti P, Aebersold R. Selected reaction monitoringbased proteomics: workflows, potential, pitfalls and future directions. Nat. Meth. 9(6), 555-566 (2012).
3. Boja ES, Rodriguez H. Mass spectrometry-based targeted quantitative proteomics: achieving sensitive and reproducible detection of proteins. Proteomics 12, 1093-1110 (2012).
4. Percy AJ, Chambers AG, Yang J, Hardie DB, Borchers CH. Advances in multiplexed MRM-based protein biomarker quantitation toward clinical utility. Biochim. Biophys. Acta 1844(5), 917-926 (2014).
5. Anderson L, Hunter CL. Quantitative mass spectrometric multiple reaction monitoring assays for major plasma proteins. Mol. Cell. Proteomics 5(4), 573-588 (2006).
6. Percy AJ, Byrns S, Chambers AG, Borchers CH. Targeted quantitation of CVD-linked plasma proteins for biomarker verification and validation. Expert Rev. Proteomics 10(6), 567-578 (2013).
7. Gerszten RE, Asnani A, Carr SA. Status and prospects for discovery and verification of new biomarkers of cardiovascular disease by proteomics. Circ. Res. 109(4), 463-474 (2011).
8. Chambers AG, Percy AJ, Simon R, Borchers CH. MRM for the verification of cancer biomarker proteins: recent applications to human plasma and serum. Expert Rev. Proteomics 11(2), 137-148 (2014).
9. Pan S, Chen R, Brand RE et al. Multiplex targeted proteomic assay for biomarker detection in plasma: a pancreatic cancer biomarker case study. J. Proteome Res. 11(3), 1937-1948 (2012).
10. Reumer A, Maes E, Mertens I et al. Colorectal cancer biomarker discovery and validation using LC-MS/MS-based proteomics in blood: truth or dare?. Expert Rev. Proteomics 11(4), 449-463 (2014).
11. Domanski D, Murphy LC, Borchers CH. Assay development for the determination of phosphorylation stoichiometry using multiple reaction monitoring methods with and without phosphatase treatment: application to breast cancer signaling pathways. Anal. Chem. 82(13), 5610-5620 (2010).
12. Zhao Y, Brasier AR. Applications of selected reaction monitoring (SRM)-mass spectrometry (MS) for quantitative measurement of signaling pathways. Methods 61(3), 313-322 (2013).
13. Omenn GS. The HUPO human plasma proteome project. Proteomics Clin. Appl. 1(8), 769-779 (2007).
14. Ivanov AR, Colangelo CM, Dufresne CP et al. Interlaboratory studies and initiatives developing standards for proteomics. Proteomics 13(6), 904-909 (2013).
15. Percy AJ, Parker CE, Borchers CH. Pre-Analytical and analytical variability in absolute quantitative MRM-based plasma proteomic studies. Bioanalysis 5(22), 2837-2856 (2013).
16. Krüger T, Lehmann T, Rhode H. Effect of quality characteristics of single sample preparation steps in the precision and coverage of proteomic studies-A review. Anal. Chim. Acta 776, 1-10 (2013).
17. Wu SL, Choudhary G, Ramström M, Bergquist J, Hancock WS. Evaluation of shotgun sequencing for proteomic analysis of human plasma using HPLC coupled with either ion trap or Fourier transform mass spectrometry. J. Proteome Res. 2(4), 383-393 (2003).
18. Malm J, Fehniger TE, Danmyr P et al. Developments in biobanking workflow standardization providing sample integrity and stability. J. Proteomics 95, 38-45 (2013).
19. Marko-Varga G, Végvári A, Welinder C et al. Standardization and utilization of biobank resources in clinical protein science with examples of emerging applications. J. Proteome Res. 11(11), 5124-5134 (2012).
20. Vaught J, Lockhart NC. The evolution of biobanking best practices. Clin. Chim. Acta 413(19-20), 1569-1575 (2012).
21. Escher C, Reiter L, MacLean B et al. Using iRT, a normalized retention time for more targeted measurement of peptides. Proteomics 12(8), 1111-1121 (2012).
22. Eyers CE, Simpson DM, Wong SC, Beynon RJ, Gaskell SJ. QCAL-A novel standard for assessing instrument conditions for proteome analysis. J. Am. Soc. Mass Spectrom. 19(9), 1275-1280 (2008).
23. Lebert D, Louwagie M, Goetze S et al. DIGESTIF: a universal quality standard for the control of bottom-up proteomics experiments. J. Proteome Res. 14(2), 787-803 (2015).
24. Percy AJ, Chambers AG, Yang J, Borchers CH. Multiplexed MRM-based quantitation of candidate cancer biomarker proteins in undepleted and non-enriched human plasma. Proteomics 13, 2202-2215 (2013).
25. Kuzyk MA, Parker CE, Domanski D, Borchers CH. Development of MRM-based assays for the absolute quantitation of plasma proteins. Methods Mol. Biol. 1023, 53-82 (2013).
26. Percy AJ, Simon R, Chambers AG, Borchers CH. Enhanced sensitivity and multiplexing with 2D LC/MRM-MS and labeled standards for deeper and more comprehensive protein quantitation. J. Proteomics 106, 113-124 (2014).
27. Kuzyk MA, Smith D, Yang J et al. Multiple reaction monitoring-based, multiplexed, absolute quantitation of 45 proteins in human plasma. Mol. Cell. Proteomics 8(8), 1860-1877 (2009).
28. Mohammed Y, Percy AJ, Chambers AG, Borchers CH. Qualis-SIS: automated standard curve generation and quality assessment for multiplexed targeted quantitative proteomic experiments with labeled standards. J. Proteome Res. 14(2), 1137-1146 (2015).
29. Percy AJ, Chambers AG, Smith DS, Borchers CH. Standardized protocols for quality control of MRM-based plasma proteomic workflow. J. Proteome Res. 12(1), 222-233 (2013).
30. Domanski D, Percy AJ, Yang J et al. MRM-based multiplexed quantitation of 67 putative cardiovascular disease biomarkers in human plasma. Proteomics 12(8), 1222-1243 (2012).
31. Farrah T, Deutsch EW, Omenn GS et al. A high-confidence human plasma proteome reference set with estimated concentrations in PeptideAtlas. Mol. Cell. Proteomics 10(9), M110.006353 (2011).
32. Kiernan UA, Phillips DA, Trenchevska O, Nedelkov D. Quantitative mass spectrometry evaluation of human retinol binding protein 4 and related variants. PLoS ONE 6(3), e17282 (2011).
33. Tu C, Rudnick PA, Martinez MY et al. Depletion of abundant plasma proteins and limitations of plasma proteomics. J. Proteome Res. 9(10), 4982-4991 (2010).
34. Polanski M, Anderson NL. A list of candidate cancer biomarkers for targeted proteomics. Biomarker Insights 2(1), 1-48 (2007).
35. Hortin GL, Sviridov D, Anderson NL. High-Abundance polypeptides of the human plasma proteome comprising the top 4 logs of polypeptide abundance. Clin. Chem. 54, 1608-1616 (2008).
36. Josic D, Brown MK, Huang F et al. Proteomic characterization of inter-Alpha inhibitor proteins from human plasma. Proteomics 6(9), 2874-2885 (2006).
37. Haab BB, Geierstanger BH, Michailidis G et al. Immunoassay and antibody microarray analysis of the HUPO Plasma Proteome Project reference specimens: systematic variation between sample types and calibration of mass spectrometry data. Proteomics 5(13), 3278-3291 (2005).
38. Anderson L. Candidate-based proteomics in the search for biomarkers of cardiovascular disease. J. Physiol. 563, 23-60 (2005).
39. Griffin JH, Gruber A, Fernández JA. Reevaluation of total, free, and bound protein S and C4b-binding protein levels in plasma anticoagulated with citrate or hirudin. Blood 79(12), 3203-3211 (1992).
40. Argraves WS, Tran H, Burgess WH, Dickerson K. Fibulin is an extracellular matrix and plasma glycoprotein with repeated domain structure. J. Cell Biol. 111(6 Pt 2), 3155-3164 (1990).
41. Agger SA, Marney LC, Hoofnagle AN. Simultaneous quantification of apolipoprotein a-I and apolipoprotein B by liquid-chromatography-multiple-reaction-monitoring mass spectrometry. Clin. Chem. 56(12), 1804-1813 (2010).
42. MacLean B, Tomazela DM, Shulman N et al. Skyline: an open source document editor for creating and analyzing targeted proteomics experiments. Bioinformatics. 26(7), 966-968 (2010).
43. Skyline. Skyline Targeted Proteomics Environment. https://skyline.gs.washington.edu
44. Makawita S, Diamandis EP. The bottleneck in the cancer biomarker pipeline and protein quantification through mass spectrometry-based approaches: current strategies for candidate verification. Clin. Chem. 56, 212-222 (2010).
45. Percy AJ, Chambers AG, Yang J, Domanski D, Borchers CH. Comparison of standard-And nano-flow liquid chromatography platforms for MRM-based quantitation of putative plasma biomarker proteins. Anal. Bioanal. Chem. 404(4), 1089-1101 (2012).
46. Keshishian H, Addona T, Burgess M et al. Quantification of cardiovascular biomarkers in patient plasma by targeted mass spectrometry and stable isotope dilution. Mol. Cell. Proteomics 8, 2339-2349 (2009).
47. US-Food-And-Drug-Administration. Guidance for Industry Bioanalytical Method Validation-September 2013 Biopharmaceuticals (2013). www.fda.gov
48. Wang Q, Chaerkady R, Wu J et al. Mutant proteins as cancer-specific biomarkers. Proc. Natl Acad. Sci. USA 108(6), 2444-2449 (2011).
49. Whiteaker JR, Zhao L, Lin C, Yan P, Wang P, Paulovich AG. Sequential multiplexed analyte quantification using peptide immunoaffinity enrichment coupled to mass spectrometry. Mol. Cell. Proteomics 11(6), M111.015347 (2012).
50. Whiteaker JR, Zhao L, Anderson L, Paulovich AG. An automated and multiplexed method for high throughput peptide immunoaffinity enrichment and multiple reaction monitoring mass spectrometry-based quantification of protein biomarkers. Mol. Cell. Proteomics 9(1), 184-196 (2010).
51. Shi T, Fillmore TL, Sun X et al. Antibody-free, targeted mass-spectrometric approach for quantification of proteins at low picogram per milliliter levels in human plasma/serum. Proc. Natl Acad. Sci. USA 109(38), 15395-15400 (2012).
52. Whiteaker JR, Halusa GN, Hoofnagle AN et al. CPTAC assay portal: a repository of targeted proteomic assays. Nat. Meth. 11(7), 703-704 (2014).
53. Füzéry AK, Levin J, Chan MM, Chan DW. Translation of proteomic biomarkers into FDA approved cancer diagnostics: issues and challenges. Clin. Prot. 10(1), 13 (2013).
54. Abbatiello SE, Schilling B, Mani DR et al. Large-scale interlaboratory study to develop, analytically validate and apply highly multiplexed, quantitative peptide assays to measure cancer-relevant proteins in plasma. Mol. Cell. Proteomics 14(9), 2357-2374 (2015).
55. Kuhn E, Whiteaker JR, Mani DR et al. Interlaboratory evaluation of automated, multiplexed peptide immunoaffinity enrichment coupled to multiple reaction monitoring mass spectrometry for quantifying proteins in plasma. Mol. Cell. Proteomics 11(6), M111.013854 (2012).
56. Prakash A, Rezai T, Krastins B et al. Interlaboratory reproducibility of selective reaction monitoring assays using multiple upfront analyte enrichment strategies. J. Proteome Res. 11(8), 3986-3995 (2012).
57. Percy AJ, Tamura-Wells J, Albar JP et al. Inter-laboratory evaluation of instrument platforms and experimental workflows for quantitative accuracy and reproducibility assessment. EuPA Open Proteomics 8, 6-15 (2015).
58. Hoofnagle AN, Becker JO, Oda MN, Cavigiolio G, Mayer P, Vaisar T. Multiple-reaction monitoring-mass spectrometric assays can accurately measure the relative protein abundance in complex mixtures. Clin. Chem. 58(4), 777-778 (2012).
59. Chace DH, Kalas TA. A biochemical perspective on the use of tandem mass spectrometry for newborn screening and clinical testing. Clin. Biochem. 38(4), 296-309 (2005).
60. Regnier FE, Skates SJ, Mesri M et al. Protein-based multiplex assays: mock presubmissions to the U.S. Food and Drug Administration. Clin. Chem. 56(2), 165-171 (2010).
61. Anderson NL. The clinical plasma proteome: a survey of clinical assays for proteins in plasma and serum. Clin. Chem. 56(2), 177-185 (2010).